Denovo Biopharma Gains Global Licensure to Wuzhong’s Oncology Drug

Denovo Biopharma has acquired the global rights, outside China, to oncology drug endostatin from Chinese drugmaker Wuzhong Pharmaceutical.

Endostatin, which Denovo has renamed DB108, is a recombinant protein drug meant to inhibit tumor growth by blocking the production of new blood vessels. In a phase 3 study, Wuzhong evaluated DB108 for nonsmall-cell lung cancer, where it was said to significantly improve progression-free survival in participants.

San Diego, Calif.-based Denovo said the deal enables its “expansion into the field of protein therapeutics.”